Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Healios KK ( (JP:4593) ) has shared an update.
Healios K.K. announced the termination of its collaboration discussions with Nobelpharma for the development and commercialization of MultiStem for ARDS in Japan. The decision came after both companies could not agree on terms, as the need for a Phase 3 clinical trial in Japan and its associated costs were deemed unnecessary. This termination does not impact the company’s financial results for the fiscal year ending December 31, 2025.
More about Healios KK
Healios K.K. operates in the biotechnology industry, focusing on regenerative medicine therapies. Its primary product, MultiStem, is a somatic stem cell therapy designed to treat conditions like acute respiratory distress syndrome (ARDS) and ischemic stroke. The company has been expanding its market focus to include global territories, aiming to advance MultiStem for various indications.
YTD Price Performance: 14.12%
Average Trading Volume: 832,611
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen18.21B
For an in-depth examination of 4593 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue